About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $91.53 | Open | $92.44 |
| Volume | 538.8K | Market Cap | 2.144B |
| Yield | Last Dividend |
| The Daily Biotech Pulse: Merck Spins Off... | 7:43 AM |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 4) A... | |
| The Daily Biotech Pulse: EyePoint In-Lic... | 02/04/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Ac... | |
| The Daily Biotech Pulse: Novartis Earnin... | 01/29/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) ... | |
| Acceleron (XLRN) Up on Success of PAH Dr... | 01/28/20 |
| Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertensio... | |
| Acceleron Stock Is Skyrocketing After Su... | 01/28/20 |
| One analyst more than doubled his price target on Acceleron Pharma stock, but others say the boom may be a bit excessive. | |
| Acceleron Hits All-Time High On Positive... | 01/28/20 |
| Shares of small-cap biopharma Acceleron Pharma Inc (NASDAQ: XLRN ) are advancing to an all-time high Tuesday following a data readout. Latest Ratings ... | |
| Acceleron Pharma stock soars more than 5... | 01/27/20 |
| Acceleron Pharma Inc. shares surged in the extended session late Monday after the biotech drug maker said its hypertension drug hit key goals in a mid... | |
| Acceleron Announces Change to Executive ... | 01/23/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-be... | |
| The Daily Biotech Pulse: Novo Nordisk's ... | 01/17/20 |
| The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs o... | |
| The Daily Biotech Pulse: Positive Data R... | 01/10/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) A... | |
| Strong Buy rating | 02/03/20 |
| Morgan Stanley upgrades from Equal-Weight to Overweight rating and raises Price Target from $52.00 to $122.00 | |
| Buy rating | 01/29/20 |
| Citigroup maintains Buy rating and raises Price Target from $75.00 to $138.00 | |
| Strong Buy rating | 01/28/20 |
| Credit Suisse maintains Outperform rating and raises Price Target from $58.00 to $99.00 | |
| Hold rating | 01/28/20 |
| and raises Price Target from $47.00 to $81.00 | |
| Strong Buy rating | 01/28/20 |
| Piper Sandler maintains Overweight rating and raises Price Target from $73.00 to $135.00 | |
| Buy rating | 01/22/20 |
| Citigroup maintains Buy rating and raises Price Target from $52.00 to $75.00 | |
| Hold rating | 12/17/19 |
| Morgan Stanley maintains Equal-Weight rating and raises Price Target from $48.00 to $52.00 | |
| Hold rating | 10/11/19 |
| Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $52.00 to $48.00 | |
| Buy rating | 09/17/19 |
| Citigroup maintains Buy rating and lowers Price Target from $61.00 to $52.00 | |
| Buy rating | 09/17/19 |
| Citi maintains Buy rating and lowers Price Target from $61.00 to $52.00 | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
XLRN - Acceleron Pharma Inc...